Loading
Total declarations
Companies
▲ Purchases (197 ops.)
▼ Sales (55 ops.)
Latest filing published 16 Oct 2026 for Grace Therapeutics, Inc., €19k. Read the official filing
Filing timeline
BuySaleOpaleye Management Inc.
First 200 filings with a declared amount
Insider track record
Disclosed buys
197
Disclosed sells
55
Signal history
Closed purchases
Market purchases
197
Positive at T+90
58%
Median T+90
+10.3%
Based on 85 purchases whose 90-day window has closed (published at least 91 days ago), the same population our ranking model reads.
Purchases by company
Since each purchase
- -9.0%Entry US$2.22 · Close at T+30 US$2.02
- +8.4%Entry US$66.79 · Close at T+30 US$72.40
- +13.8%Entry US$69.37 · Close at T+30 US$78.95
- +5.0%Entry US$69.52 · Close at T+30 US$73.00
- -1.9%Entry US$2.14 · Close at T+30 US$2.10
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Opaleye Management Inc.: trading record in brief
Opaleye Management Inc. is a declared insider at 10 companies; the most frequent names are Alpha Cognition Inc., Sol-Gel Technologies Ltd. and Tracon Pharmaceuticals, Inc. We count 253 filings; the first trade dates from 25 May 2021 and the latest from 16 October 2026.
The open-market side counts 197 purchases for €36.5M alongside 55 sales for €21.2M. The amount is not disclosed for 7 filings. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Besides market trades, the filings include 1 share grant. So far in 2026, the count stands at 87 purchases and 19 sales.
The median purchase comes to €52k. As a share of market capitalisation, the median purchase stands at 0.044%, based on 53 purchases. Clusters matter here: 50 out of 192 purchases overlapped with buying by a colleague within 30 days. When several insiders buy within a few weeks of each other, analysts speak of a cluster purchase. For 85 purchases whose 90-day window has closed, the share price was higher on day 90 than the day after publication in 58% of cases, with a median move of +10.3%. This is a record of the past, not a forecast.
Most recently, on 16 October 2026, the filings show an open-market purchase worth €41k in Grace Therapeutics, Inc. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. For comparison, the SEC allows two business days to file a Form 4. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Companies and markets linked to Opaleye Management Inc.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations242 total
11,233 shares@ US$1.9349Common Stock, par value $0.0001 per shareSEC:0001493152-26-047473:0
Canonical exit: 12 Jan 2027 (T+90)
23,485 shares@ US$1.9453Common Stock, par value $0.0001 per shareSEC:0001493152-26-047473:1
Canonical exit: 13 Jan 2027 (T+90)
36,347 shares@ US$1.8917Common Stock, par value $0.0001 per shareSEC:0001493152-26-047473:2
Canonical exit: 14 Jan 2027 (T+90)
2,077 shares@ US$2.01750.0099% mcap1.7% of flowCommon Stock, par value $0.0001 per shareSEC:0001493152-26-046899:0
Canonical exit: 6 Jan 2027 (T+90)
5,340 shares@ US$2.04460.026% mcap4.3% of flowCommon Stock, par value $0.0001 per shareSEC:0001493152-26-046899:1
Canonical exit: 7 Jan 2027 (T+90)
7,215 shares@ US$2.020.034% mcap5.7% of flowCommon Stock, par value $0.0001 per shareSEC:0001493152-26-046899:2
Canonical exit: 10 Jan 2027 (T+90)
38,796 shares@ US$2.03530.18% mcap34.8% of flowCommon Stock, par value $0.0001 per shareSEC:0001493152-26-045809:0
Canonical exit: 30 Dec 2026 (T+90)
20,000 shares@ US$2.06840.095% mcap18.4% of flowCommon Stock, par value $0.0001 per shareSEC:0001493152-26-045809:1
Canonical exit: 31 Dec 2026 (T+90)
1,694 shares@ US$2.060.0080% mcap1.6% of flowCommon Stock, par value $0.0001 per shareSEC:0001493152-26-045809:2
Canonical exit: 3 Jan 2027 (T+90)
19,050 shares@ US$8.69470.087% mcap3.1% of flowCommon Stock, no par valueSEC:0001493152-26-045511:0
Canonical exit: 30 Dec 2026 (T+90)
7,849 shares@ US$2.090.037% mcap16.0% of flowCommon Stock, par value $0.0001 per shareSEC:0001493152-26-045358:0
Canonical exit: 28 Dec 2026 (T+90)
18,337 shares@ US$8.56640.085% mcap3.0% of flowCommon Stock, no par valueSEC:0001493152-26-044690:0
Canonical exit: 23 Dec 2026 (T+90)
13,426 shares@ US$8.470.062% mcap2.2% of flowCommon Stock, no par valueSEC:0001493152-26-044690:1
Canonical exit: 24 Dec 2026 (T+90)
9,771 shares@ US$2.100.045% mcap23.5% of flowCommon Stock, par value $0.0001 per shareSEC:0001493152-26-043996:0
Canonical exit: 20 Dec 2026 (T+90)
5,318 shares@ US$2.100.024% mcap12.8% of flowCommon Stock, par value $0.0001 per shareSEC:0001493152-26-043996:1
Canonical exit: 22 Dec 2026 (T+90)
40,373 shares@ US$8.6960.18% mcap6.9% of flowCommon Stock, no par valueSEC:0001493152-26-042969:0
Canonical exit: 13 Dec 2026 (T+90)
3,375 shares@ US$8.54240.015% mcap0.6% of flowCommon Stock, no par valueSEC:0001493152-26-042969:1
Canonical exit: 14 Dec 2026 (T+90)
53,029 shares@ US$8.57280.24% mcap9.0% of flowCommon Stock, no par valueSEC:0001493152-26-042969:2
Canonical exit: 15 Dec 2026 (T+90)
27,141 shares@ US$8.400.12% mcap4.5% of flowCommon Stock, no par valueSEC:0001493152-26-042969:3
Canonical exit: 15 Dec 2026 (T+90)
1,631 shares@ US$66.7950.049% mcap1.4% of flowOrdinary Shares, par value NIS 1.00 per shareSEC:0001493152-26-042615:0
Canonical exit: 9 Dec 2026 (T+90)
1,493 shares@ US$65.9450.044% mcap1.3% of flowOrdinary Shares, par value NIS 1.00 per shareSEC:0001493152-26-042615:1
Canonical exit: 10 Dec 2026 (T+90)
9,393 shares@ US$2.09720.042% mcap22.3% of flowCommon Stock, par value $0.0001 per shareSEC:0001493152-26-042152:0
Canonical exit: 7 Dec 2026 (T+90)
5,836 shares@ US$2.08990.026% mcap13.8% of flowCommon Stock, par value $0.0001 per shareSEC:0001493152-26-042152:1
Canonical exit: 8 Dec 2026 (T+90)
918 shares@ US$69.520.029% mcap0.8% of flowOrdinary Shares, par value NIS 1.00 per shareSEC:0001493152-26-042023:0
Canonical exit: 3 Dec 2026 (T+90)
2,100 shares@ US$68.980.065% mcap1.9% of flowOrdinary Shares, par value NIS 1.00 per shareSEC:0001493152-26-042023:1
Canonical exit: 3 Dec 2026 (T+90)
25 of 242 declarations
